Abstract 4367390: Trend in the Utilization of Colchicine For Coronary Artery Disease In the United States Over the Past Decade: Insights From Real-World Data

Introduction: Colchicine has emerged as a promising anti-inflammatory therapy for secondary prevention in coronary artery disease (CAD). Despite growing evidence supporting its cardiovascular benefits, real-world utilization patterns remain poorly characterized. This study examines trends in colchicine use among patients with coronary artery disease (CAD) over the past decade. Methods: We conducted a retrospective cohort study using TriNetX US collaborative network. Adult patients (≥18 years) with ischemic heart disease were included, while those with a diagnosis of gout were excluded. Annual colchicine prescription data were collected from 2015 to 2024. The utilization rates (prescriptions per/100,000 person-day) of Colchicine for coronary artery disease were calculated and stratified by sex, race, and ethnicity. Results: Among 6.1 million patients with CAD, colchicine use increased steadily over the past decade. The overall proportion of colchicine use rose from 0.13% in 2015 to 0.47% in 2024, a 261% increase, and the utilization rate increased from 3.76 to 15.49 per 100,000 person-days, a 312% increase. Sex-based analysis revealed that in 2024, males had higher utilization (0.55%; 18.11) compared to females (0.39%; 12.35). Race-stratified data from 2024 showed the highest utilization rate among African American patients (0.53%; 17.3), followed by Asian (0.48%; 15.9), and White (0.47%; 14.9) patients. Native Hawaiians had the lowest utilization (0.33%; 13.9). Non-Hispanic patients had slightly higher utilization (0.49%; 15.7) than Hispanic patients (0.45%; 14.8), though both groups saw a fivefold increase since 2015. Conclusion: Colchicine use among patients with CAD has increased meaningfully over the past decade; however, absolute utilization for cardiovascular risk reduction remains low. Persistent disparities in prescribing patterns by sex, race, and ethnicity underscore the need for more equitable implementation.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4367390
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4367390: Trend in the Utilization of Colchicine For Coronary Artery Disease In the United States Over the Past Decade: Insights From Real-World Data

Huda El Mais, Karnav Modi, Muhammad Ishaq, Hima Sanjana Perumalla et al.
Circulation
Inflammasome and immune disorders
article

Abstract 4367390: Trend in the Utilization of Colchicine For Coronary Artery Disease In the United States Over the Past Decade: Insights From Real-World Data

Huda El Mais, Karnav Modi, Muhammad Ishaq, Hima Sanjana Perumalla, David Gonzalez Sanchez, Talal Asif, Daniel Paulino-González, Irfan Ullah, Abdul Wali Khan
article en

Abstract

Introduction: Colchicine has emerged as a promising anti-inflammatory therapy for secondary prevention in coronary artery disease (CAD). Despite growing evidence supporting its cardiovascular benefits, real-world utilization patterns remain poorly characterized. This study examines trends in colchicine use among patients with coronary artery disease (CAD) over the past decade. Methods: We conducted a retrospective cohort study using TriNetX US collaborative network. Adult patients (≥18 years) with ischemic heart disease were included, while those with a diagnosis of gout were excluded. Annual colchicine prescription data were collected from 2015 to 2024. The utilization rates (prescriptions per/100,000 person-day) of Colchicine for coronary artery disease were calculated and stratified by sex, race, and ethnicity. Results: Among 6.1 million patients with CAD, colchicine use increased steadily over the past decade. The overall proportion of colchicine use rose from 0.13% in 2015 to 0.47% in 2024, a 261% increase, and the utilization rate increased from 3.76 to 15.49 per 100,000 person-days, a 312% increase. Sex-based analysis revealed that in 2024, males had higher utilization (0.55%; 18.11) compared to females (0.39%; 12.35). Race-stratified data from 2024 showed the highest utilization rate among African American patients (0.53%; 17.3), followed by Asian (0.48%; 15.9), and White (0.47%; 14.9) patients. Native Hawaiians had the lowest utilization (0.33%; 13.9). Non-Hispanic patients had slightly higher utilization (0.49%; 15.7) than Hispanic patients (0.45%; 14.8), though both groups saw a fivefold increase since 2015. Conclusion: Colchicine use among patients with CAD has increased meaningfully over the past decade; however, absolute utilization for cardiovascular risk reduction remains low. Persistent disparities in prescribing patterns by sex, race, and ethnicity underscore the need for more equitable implementation.

CirculationVol. 152(Suppl_3)
Saint Luke's Health System (US), Universidad Autónoma Metropolitana (MX), Khyber Teaching Hospital (PK), Unity Health System (US), Universidad Marista (MX), Saint Luke's Hospital (US), University of Missouri–Kansas City (US)
Openalex Percentile: Top 71%
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.